BI-D1870

SKU: orb1301013

Description

BI-D1870

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 501437-28-1
• MW: 391.42
• Purity: 99.43%
• Formula: C₁₉H₂₃F₂N₅O₂
• SMILES: CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12
• Target: Autophagy,S6 Kinase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:7.2 mg/mL (18.39 mM);DMSO:16.9 mg/mL (43.18 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  RSK3:18 nM (cell free)|RSK2:24 nM (cell free)|RSK1:31 nM (cell free)|RSK4:15 nM (cell free)
• In Vivo:
  METHODS: Two days after immunization with MOG peptide, BI-D1870 (0.5 mg/kg) was injected intraperitoneally into mice and repeated every other day for 11 days. RESULTS Mice showed delayed neurological deficits; BI-D1870 treatment had a moderate protective effect against weight loss.
• In Vitro:
  METHODS: HEK-293 cells were incubated with BI-D1870 (10 μM, 15 min, 4 h total) To examine whether BI-D1870 could inhibit RSK activity in cells, the effect of BI-D1870 on RSK-catalyzed phosphorylation of its known substrates in HEK-293 cells was investigated using PMA as an agonist to activate ERK1/ERK2 and RSK isoforms. RESULTS Incubation of cells with BI-D1870 significantly inhibited PMA-induced phosphorylation of GSK3α and GSK3β. In contrast, BI-D1870 had little effect on PMA-induced activation of ERK1/ERK2 (catalyzed by Raf and MKK1) or phosphorylation of CREB at Ser at any time point. METHODS: Oral cancer cell lines (SCC2095, SCC4, SCC9, Ca922 and HSC-3) and NHOK cells were treated with BI-D1870 (1, 2, 3, 4, 5.28 or 48 hours), and the growth of these cells was detected by MTT. RESULTS BI-D1870 showed a dose-responsive antiproliferative effect on OSCC cells. METHODS: Cells transfected with immunofluorescent GFP-LC3 were treated with BI-D1870 (0.5, 2 μM) for 48 hours and observed under a confocal microscope; DAPI staining was used to locate the nucleus, and Western blot of LC3B was observed in cells treated with BI-D1870 for 48 hours. RESULTS BI-D1870 induced autophagy, and Western blot of LC3B-II showed that this induction was dose-dependent.
• Cell Research:
  The rat embryo fibroblast cell line, Rat-2 cells were cultured on 10 cm-diameter dishes in Dulbecco's Modified Eagle's medium supplemented with 10% (v/v) FBS. HEK-293 cells were cultured on 10 cm-diameter dishes in Dulbecco's Modified Eagle's medium supplemented with 10% FBS and 1×antimycotic/antibiotic solution. Prior to stimulation, cells were cultured in the absence of serum for 16 h. Inhibitors were dissolved in DMSO at a 1000-fold higher concentration than they were used at. These inhibitors, or the equivalent volume of DMSO as a control, were added to the tissue culture medium 30 min prior to stimulation unless indicated otherwise. The final concentration of DMSO in the culture medium was 0.1% and had no effect on agonist-induced activation or phosphorylation of any of the substrates examined. The cells were stimulated with the indicated agonists and lysed in 1 ml of ice-cold Lysis Buffer and centrifuged at 16000 g at 4 °C for 5 min. The supernatants were frozen in liquid nitrogen and stored at 80 °C until use. Protein concentrations were determined using the Bradford method with BSA as the standard .
• Animal Research:
  Myelin oligodendrocyte glycoprotein (MOG) peptide 35–55. (MEVGWYRSPFSRVVHLYRNGK) (BEX) was used to induce EAE in C57/BL6J mice. Mice were injecteds.c. with 200 g of MOG peptide in100 L of PBS emulsified in 100 L complete Freund's adjuvant (CFA) that was further supplemented with five mg mL 1 Mycobacterium tuberculosis (H37Ra). In addition, 500 ng pertussis toxin was injected i.p. on days zero and two. The RSK inhibitor (BI-D1870; 0.5 mg kg 1) was injected i.p. into mice two days after immunization with MOG peptide, and injection was repeated every other day for 11 days. Mice that received only dimethyl sulfoxide (DMSO) solution were used as controls. Paralysis was evaluated according to the following scale: zero, no disease; one, tail limpness; two, hind limb weakness; three, hind limb paralysis; four, forelimb weakness; five, quadriplegia; six, death. For histological analysis, CNS samples were fixed with 4% paraformaldehyde and sliced at 4 m, and then hematoxylin & eosin (H & E) staining was performed .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

S6Kinase, S6 Kinase, S6K, RSK2, RSK4, RSK1, RSK3, Ribosomal S6 Kinase (RSK), inhibit, Inhibitor, Autophagy, BI D1870, BI-D 1870, BID1870, BI-D1870, BI-D-1870

Compound Identifiers

PubChem CID

25023738